| Literature DB >> 28974511 |
Riadh Lobbardi1,2,3, Jordan Pinder4,5, Barbara Martinez-Pastor2, Marina Theodorou1,2,3, Jessica S Blackburn6, Brian J Abraham7, Yuka Namiki8, Marc Mansour9,10, Nouran S Abdelfattah1,2, Aleksey Molodtsov1,2, Gabriela Alexe9,11, Debra Toiber2,12, Manon de Waard13, Esha Jain1,14, Myriam Boukhali2, Mattia Lion8, Deepak Bhere15, Khalid Shah15, Alejandro Gutierrez16, Kimberly Stegmaier9,11,16, Lewis B Silverman9,16, Ruslan I Sadreyev1,14, John M Asara17, Marjorie A Oettinger8, Wilhelm Haas2, A Thomas Look9, Richard A Young7, Raul Mostoslavsky2,14, Graham Dellaire4,5, David M Langenau18,2,3,14.
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using a transgenic screen in zebrafish, thymocyte selection-associated high mobility group box protein (TOX) was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in a majority of human T-ALL and is required for proliferation and continued xenograft growth in mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit nonhomologous end joining (NHEJ) repair. Impaired NHEJ is well known to cause genomic instability, including development of T-cell malignancies in KU70- and KU80-deficient mice. Collectively, our work has uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during leukemia initiation and sustaining leukemic cell proliferation following transformation.Significance: TOX is an HMG box-containing protein that has important roles in T-ALL initiation and maintenance. TOX inhibits the recruitment of KU70/KU80 to DNA breaks, thereby inhibiting NHEJ repair. Thus, TOX is likely a dominant oncogenic driver in a large fraction of human T-ALL and enhances genomic instability. Cancer Discov; 7(11); 1336-53. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1201. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28974511 PMCID: PMC5683427 DOI: 10.1158/2159-8290.CD-17-0267
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397